Magnetic Resonance Fingerprinting for Brain Cancer

Overseen By Chaitra A Badve, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Case Comprehensive Cancer Center

Disqualifiers: Pregnancy, Pacemaker, Claustrophobia, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Varies based on individual treatment plans

84 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of the research study is to test new methods that could improve diagnosis and assessment of brain tumors. One of these methods is a new MR (magnetic resonance) imaging technique called magnetic resonance fingerprinting (MRF), which allows for rapidly scanning the patient and provides quantitative information on tumor tissue. The investigators will compare the data gathered from MR Fingerprinting with other imaging tests, clinical information, treatment details and biopsy results to evaluate the accuracy of this new technique.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Magnetic Resonance Fingerprinting for brain cancer?

Magnetic Resonance Fingerprinting (MRF) is a promising tool for diagnosing brain tumors by providing detailed maps of tissue properties, which can help distinguish between tumor and normal brain tissue. It has been used in various clinical applications, including brain tumor characterization, and shows potential in predicting tumor regions and grading when combined with other imaging techniques like PET. ^{1 2 3 4 5}

Is Magnetic Resonance Fingerprinting (MRF) safe for humans?

The research on Magnetic Resonance Fingerprinting (MRF) does not specifically address safety concerns, but it has been used in various clinical applications, including brain, prostate, liver, and cardiac imaging, suggesting it is generally considered safe for human use. ^{1 4 5 6 7}

How is Magnetic Resonance Fingerprinting different from other brain cancer treatments?

Magnetic Resonance Fingerprinting (MRF) is unique because it provides rapid, simultaneous mapping of multiple tissue properties, like T1 and T2 relaxation times, which helps in distinguishing tumor characteristics and grades. Unlike traditional imaging, MRF offers a quantitative approach, potentially improving diagnosis and treatment planning for brain cancer. ^{2 3 4 6 8}

Research Team

Chaitra A Badve, MD

Principal Investigator

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Eligibility Criteria

This trial is for adults with a new or previously treated brain tumor who can give informed consent themselves or through a legal representative. It's not for those with non-MRI safe implants, metallic foreign objects in their body, severe claustrophobia, pregnant women, prisoners, vulnerable populations, non-English speakers, or minors.

Inclusion Criteria

I can understand and am willing to sign the consent form, or I have someone legally authorized to do so on my behalf.

I have brain metastases and can have scans at specified times after targeted brain radiation.

I have a brain tumor that was either found at the start or has shown signs of growth on scans.

Exclusion Criteria

Patients with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material

Implanted medical device not described above that is not MRI-compatible

I am under 18 years old.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Imaging and Diagnosis

Participants undergo volumetric MRI study with contrast and 3D-MRF acquisition for surgical planning or clinical diagnosis

1-2 weeks

Treatment

Participants receive standard of care surgery, radiation, and chemotherapy

Varies based on individual treatment plans

Follow-up Imaging

Follow-up MRF scans are performed to visualize recurrence and differentiate post-treatment changes from tumor recurrence

Ongoing as determined by clinical care

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Treatment Details

Interventions

• Magnetic Resonance Fingerprinting

Trial Overview The study tests Magnetic Resonance Fingerprinting (MRF), an advanced MR imaging technique that quickly scans and provides detailed tissue data. This will be compared to standard imaging and clinical information to check its accuracy in diagnosing and assessing brain tumors.

Participant Groups

Group I: Treated tumors with possible recurrence Experimental Treatment 1 Intervention

Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.

Group II: Newly Diagnosed Brain Tumors Experimental Treatment 1 Intervention

Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials

472

Recruited

33,400+

Findings from Research

Magnetic Resonance Fingerprinting (MRF) is a cutting-edge imaging technique that allows for the simultaneous and efficient measurement of multiple tissue properties, which could lead to more accurate and objective diagnoses.

MRF has shown promise in various applications, including brain, prostate, liver, and cardiac imaging, as well as in assessing microvascular properties, indicating its potential to enhance patient monitoring and the development of imaging biomarkers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting-An Overview. Panda, A., Mehta, BB., Coppo, S., et al.[2020]

Magnetic Resonance Fingerprinting (MRF) demonstrated a high predictability for identifying tumor regions and grading in gliomas, achieving 88.9% accuracy for low-grade gliomas and 75% for high-grade gliomas among 17 patients studied.

While both MRF and PET imaging provide valuable quantitative data on gliomas, they reflect different biological mechanisms, indicating that they may complement each other rather than replace one another in clinical assessments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of Gliomas with Magnetic Resonance Fingerprinting with PET Correlation-A Comparative Study. Marik, W., Cardoso, PL., Springer, E., et al.[2023]

Magnetic resonance fingerprinting (MRF) can quickly and effectively differentiate between tumor tissue and normal white matter in pediatric brain tumor patients, with a median scan time of just 11 minutes.

MRF successfully distinguishes between low-grade and high-grade tumors based on T1 and T2 relaxation times, indicating its potential as a valuable diagnostic tool for assessing tumor characteristics in children and young adults.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors. de Blank, P., Badve, C., Gold, DR., et al.[2020]

Magnetic resonance fingerprinting (MRF) is a cutting-edge MRI technology that can simultaneously generate multiple high-resolution property maps, such as T1, T2, and ADC measurements, which are useful for various clinical applications including brain tumors and prostate cancer.

Despite its rapid development and potential, MRF still faces challenges that need to be addressed to fully establish it as a reliable quantitative imaging biomarker in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic resonance fingerprinting: an overview. Tippareddy, C., Zhao, W., Sunshine, JL., et al.[2021]

Magnetic resonance fingerprinting (MRF) is a promising imaging technique that allows for the simultaneous measurement of multiple tissue properties, leading to the creation of accurate and reproducible quantitative maps.

The review highlights the expanding applications of MRF in various fields, including neuroimaging, prostate, liver, kidney, and cardiac imaging, indicating its potential for broad clinical use.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting: A Review of Clinical Applications. Gaur, S., Panda, A., Fajardo, JE., et al.[2023]

The study successfully demonstrated the feasibility of using MR fingerprinting (MRF) for 3D whole-brain T1 and T2 mapping on a 0.55 T MRI system, achieving high spatial resolution and a quick acquisition time of 8.5 minutes.

T1 and T2 values obtained from MRF were highly correlated with standard measurements, showing strong accuracy and precision (less than 5%) even in the lower signal-to-noise ratio environment of 0.55 T.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Feasibility of MR fingerprinting using a high-performance 0.55 T MRI system. Campbell-Washburn, AE., Jiang, Y., Körzdörfer, G., et al.[2022]

MR fingerprinting (MRF) is a reliable technique for assessing tissue relaxation times, showing a strong correlation between measured and reference values in a phantom study, which supports its accuracy for clinical use.

In a study of 20 patients with meningiomas, MRF revealed significantly longer T1 and T2 relaxation times in meningiomas compared to surrounding brain structures, indicating its potential for quantitative assessment of these tumors in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma. Mostardeiro, TR., Panda, A., Witte, RJ., et al.[2021]

Tailored magnetic resonance fingerprinting (TMRF) can rapidly provide quantitative maps (T1, T2) and qualitative images in pediatric brain tumor patients, potentially saving about 2 minutes in imaging time.

In a study of five pediatric patients, TMRF-derived T2 weighted images showed strong correlation with standard imaging methods, indicating its effectiveness in differentiating between healthy and pathological tissues.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tailored magnetic resonance fingerprinting of post-operative pediatric brain tumor patients. Poojar, P., Qian, E., Jin, Z., et al.[2023]

References

1. England pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting-An Overview. [2020]

2. Switzerland pubmed.ncbi.nlm.nih.gov

Evaluation of Gliomas with Magnetic Resonance Fingerprinting with PET Correlation-A Comparative Study. [2023]

3. Switzerland pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting to Characterize Childhood and Young Adult Brain Tumors. [2020]

4. Germany pubmed.ncbi.nlm.nih.gov

Magnetic resonance fingerprinting: an overview. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Magnetic Resonance Fingerprinting: A Review of Clinical Applications. [2023]

6. Netherlands pubmed.ncbi.nlm.nih.gov

Feasibility of MR fingerprinting using a high-performance 0.55 T MRI system. [2022]

7. Germany pubmed.ncbi.nlm.nih.gov

Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma. [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Tailored magnetic resonance fingerprinting of post-operative pediatric brain tumor patients. [2023]